Brain death induced renal injury

Current Opinion in Organ Transplantation

Volumn 16, Issue 2, 2011, Pages 151-156

  Westendorp, Welmoet H ^a   Leuvenink, Henri G ^a   Ploeg, Rutger J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Brain death; deceased brain dead donor; kidney transplantation; renal injury

Indexed keywords

ACETYLGLUCOSAMINIDASE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ARGIPRESSIN; BIOLOGICAL MARKER; CATECHOLAMINE; DOPAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROPOIETIN; FATTY ACID BINDING PROTEIN; FIBRINOGEN; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KIDNEY INJURY MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PROTOPORPHYRIN COBALT; PROTOPORPHYRIN ZINC; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN DEATH; CADAVER KIDNEY; DELAYED GRAFT FUNCTION; GENE EXPRESSION; GRAFT SURVIVAL; HORMONAL REGULATION; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

BRAIN DEATH; DONOR SELECTION; GRAFT SURVIVAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 79954587087     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328344a5dc     Document Type: Article

References (35)

1. Mollaret P, Goulon M. The depassed coma (preliminary memoir). Rev Neurol (Paris) 1959; 101:3-15.
2. A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. JAMA 1968; 205:337-340.
3. Bos EM, Leuvenink HG, van Goor H, Ploeg RJ. Kidney grafts from brain dead donors: inferior quality or opportunity for improvement? Kidney Int 2007; 72:797-805. (Pubitemid 47462070)
4. Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996; 24:1352-1359. (Pubitemid 26262410)
5. Powner DJ, Boccalandro C, Alp MS, Vollmer DG. Endocrine failure after traumatic brain injury in adults. Neurocrit Care 2006; 5:61-70. (Pubitemid 44379156)
6. Perez Lopez S, Otero Hernandez J, Vazquez Moreno N, et al. Brain death effects on catecholamine levels and subsequent cardiac damage assessed in organ donors. J Heart Lung Transplant 2009; 28:815-820.
7. Martikainen TJ, Kurola J, Karja V, et al. Vasopressor agents after experimental brain death: effects of dopamine and vasopressin on vitality of the small gut. Transplant Proc 2010; 42:2449-2456.
8. Schuurs TA, Gerbens F, van der Hoeven JA, et al. Distinct transcriptional changes in donor kidneys upon brain death induction in rats: insights in the processes of brain death. Am J Transplant 2004; 4:1972-1981. (Pubitemid 39611624)
9. Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. Transplantation 1988; 45:32-36. (Pubitemid 18084604)
10. Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. Am J Transplant 2009; 9:989-997.
11. Cooper DK, Novitzky D, Wicomb WN, et al. A review of studies relating to thyroid hormone therapy in brain-dead organ donors. Front Biosci 2009; 14:3750-3770.
12. Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998; 65:1533-1542. (Pubitemid 28304585)
13. Kusaka M, Kuroyanagi Y, Kowa H, et al. Genomewide expression profiles of rat model renal isografts from brain dead donors. Transplantation 2007; 83:62-70. (Pubitemid 46104972)
14. Mofarrahi M, Nouh T, Qureshi S, et al. Regulation of angiopoietin expression by bacterial lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 2008; 294:L955-L963.
15. Kumpers P, Lukasz A, David S, et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008; 12:R147.
16. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27:552-558. (Pubitemid 44780853)
17. Nijboer WN, Schuurs TA, van der Hoeven JA, et al. Effects of brain death on stress and inflammatory response in the human donor kidney. Transplant Proc 2005; 37:367-369. (Pubitemid 40459788)
18. Ledinh H, Bonvoisin C, Weekers L, et al. Results of kidney transplantation from donors after cardiac death. Transplant Proc 2010; 42:2407-2414.
19. Morariu AM, Schuurs TA, Leuvenink HG, et al. Early events in kidney donation: progression of endothelial activation, oxidative stress and tubular injury after brain death. Am J Transplant 2008; 8:933-941. (Pubitemid 351537757)
20. Kotsch K, Kunert K, Merk V, et al. Novel markers in zero-hour kidney biopsies indicate graft quality and clinical outcome. Transplantation 2010; 90:958-965.
21. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333:333-336.
22. Sanchez-Fructuoso AI, Prats D, Marques M, et al. Does donor brain death influence acute vascular rejection in the kidney transplant? Transplantation 2004; 78:142-146.
23. Robert R, Guilhot J, Pinsard M, et al. A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor. J Crit Care 2010; 25:582-590.
24. Mascia L, Mastromauro I, Viberti S, et al. Management to optimize organ procurement in brain dead donors. Minerva Anestesiol 2009; 75:125-133.
25. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009; 302:1067-1075.
26. Nijboer WN, Ottens PJ, van Dijk A, et al. Donor pretreatment with carbamylated erythropoietin in a brain death model reduces inflammation more effectively than erythropoietin while preserving renal function. Crit Care Med 2010; 38:1155-1161.
27. Nykanen AI, Krebs R, Saaristo A, et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003; 107: 1308-1314. (Pubitemid 36314416)
28. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-516. (Pubitemid 39469986)
29. Elkins LJ. Inhalational anesthesia for organ procurement: potential indications for administering inhalational anesthesia in the brain-dead organ donor. AANA J 2010; 78:293-299.
30. Nijboer WN, Moers C, Leuvenink HG, Ploeg RJ. How important is the duration of the brain death period for the outcome in kidney transplantation? Transpl Int 2010; 24:14-20.
31. Li LP, Zhang L, Peng LP, Cheng L. Heme oxygenase-1 is the candidate targeting for organ transplantation. Chin Med J (Engl) 2010; 123:2128-2134.
32. Kotsch K, Francuski M, Pascher A, et al. Improved long-term graft survival after HO-1 induction in brain-dead donors. Am J Transplant 2006; 6:477-486. (Pubitemid 43382133)
33. Ollinger R, Pratschke J. Role of heme oxygenase-1 in transplantation. Transpl Int 2010.
34. Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273:4135-4142. (Pubitemid 28103282)
35. Nijboer WN, Schuurs TA, Damman J, et al. Kidney injury molecule-1 is an early noninvasive indicator for donor brain death-induced injury prior to kidney transplantation. Am J Transplant 2009; 9:1752-1759.